Mallinckrodt bags another microcap biotech, picking up Ocera’s failed drug in $117M buyout
Back at the beginning of the year, Ocera looked like just about any other small developer after a head-on collision with bad data. Its Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
